Cancer NetworkOriginal article
<![CDATA[Mezigdomide Drives 41% ORR in Triple-Class Refractory Multiple Myeloma]]>
Data ReadoutpositivemezigdomidePositive
AI Analysis
Summary
Mezigdomide demonstrated a 41% overall response rate in triple-class refractory multiple myeloma, with mechanism related to cereblon E3 ligase engagement overcoming IMiD resistance in heavily pretreated patients.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
41% overall response rate (ORR) in triple-class refractory multiple myeloma
Importance:6/10
Sentiment:
0.75
oncologymultiple myelomacereblon E3 ligaseIMiD resistanceclinical data
Read the original article
Published by Cancer Network on July 3, 2026 2:00 PM